Brief: SPIMACO and CanSinoBIO Sign Agreement To Localise, Market MCV4 Vaccine In Saudi And MENA
26/03/2025 05:11
March 26 (Reuters) - SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORP SPIMACO ADDWAEIH 2070.SE:
ANNOUNCES CONTRACT SIGN OFF WITH CANSINO BIOLOGICS ("CANSINOBIO")
CONTRACT FOR SUPPLY, MANUFACTURING, AND COMMERCIALISATION OF MCV4 VACCINES IN SAUDI AND SELECTED MENA MARKETS
Source text: ID:nSSE7KDZTv
Further company coverage: 2070.SE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cansino Biologics
See all newsBrief: CanSino Biologics Says China's NMPA Granted Priority Review Status To NDA For TD5CP Adolescent, Adult
Brief: CanSino Biologics Reports Widened Net Loss For Q1
Brief: CanSino Biologics Says 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Prelim 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Expects To Have Returned to Net Profit In 2025